What You Ought to Know:
– ConcertAI, LLC (ConcertAI), the chief in enterprise AI and real-world knowledge (RWD) options for all times sciences and healthcare, introduced the shut of its $150M in Sequence C led by Sixth Avenue at a $1.9B valuation.
– From its startup simply 5 years in the past, ConcertAI has emerged as one of many fastest-growing corporations offering high-value software-as-a-service (SaaS) and knowledge options to life sciences and biopharma corporations, main healthcare suppliers, contract analysis organizations, medical societies, and regulators within the US, Europe, and Japan.
Accelerating Enterprise SaaS AI from Scientific Analysis to Scientific Follow
Based in 2018, ConcertAI is a developer of medical analysis instrument suite supposed to design and ship care-based oncology analysis and knowledge analytics. It’s an built-in real-world knowledge and AI-driven options to rework how insights are generated and speed up therapeutic improvements to sufferers. By means of a “system of proof” method, ConcertAI is advancing knowledge and applied sciences that underpin new fashions of medical improvement, pushed by the pandemic’s acceleration to completely digital and AI-enabled options. This contains the business’s largest, impartial oncology analysis database and affected person knowledge composed of medical, molecular, medical claims, and imaging knowledge. Up to now two years, ConcertAI has labored intently with main biopharma innovators, medical societies, the US FDA, and healthcare suppliers to advance these options for an array of regulatory and post-approval research.
The corporate has made a deep dedication to making sure the main analysis is on the market on the neighborhood and regional well being system stage, in assurance of representativeness and entry. This ecosystem of main life science corporations with main healthcare suppliers marks the primary full RWE-generation system that aligns retrospective and potential approaches right into a single system.
Up to now 36 months, the corporate has expanded its buyer base and partnerships to greater than 45 life sciences corporations and contract analysis organizations (CROs) with SaaS options throughout the product lifecycle: supporting roughly 40 new product launches, bettering time on remedy by 10%, and decreasing time for examine design and projected medical trial execution instances up to 25%. The main oncology biopharma corporations, together with Janssen and BMS, are multi-product strategic companions.
“Our Sequence C represents one other milestone in our emergence because the chief in accelerating biomedical improvements by means of AI SaaS medical trial options and improved affected person outcomes by means of the technology of real-world proof for peer-review publications, regulatory choices, and medical interpretation,” mentioned ConcertAI CEO Jeff Elton, PhD. “Our options now span the complete lifecycle of therapeutics with our data-as-a-service and AI SaaS options for biopharma by means of to our TeraRecon options for medical choice help, confederating an ecosystem of main biomedical innovators and healthcare suppliers – all in assurance of very best medical outcomes for sufferers.”